Precision engineering of nanocarriers for transport across complex biological barriers
6 affiliations
- 1School of Integrative Engineering, Chung-Ang University, Seoul, Republic of Korea
- 2Department of Chemistry, The University of Tokyo, Tokyo, 113-0033, Japan
- 3School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA
- 4Feynman Institute of Technology, Nanomedicine Corporation, Seoul, Republic of Korea; Department of Chemical Engineering, Kumoh National Institute of Technology, Gumi, Republic of Korea
- 5Department of Life Science and Technology, School of Life Science and Technology, Institute of Science Tokyo, Yokohama, Kanagawa, Japan; Corresponding author.
- 6School of Integrative Engineering, Chung-Ang University, Seoul, Republic of Korea; Feynman Institute of Technology, Nanomedicine Corporation, Seoul, Republic of Korea; Corresponding author.
Abstract
Biological barriers are essential for maintaining tissue homeostasis and protecting organs from harmful external agents; however, they also represent major obstacles to the efficient delivery of therapeutic agents. The blood–brain barrier, ocular barriers, mucosal barriers, and vascular endothelial barriers exhibit highly selective permeability that restricts the transport of both small-molecule drugs and biopharmaceuticals, thereby limiting tissue bioavailability, reducing therapeutic efficacy, and increasing the risk of systemic adverse effects. Advances in nanotechnology have enabled the development of precision-engineered nanocarriers capable of overcoming these barriers through the rational optimization of their physicochemical properties and interactions with biological interfaces. This review comprehensively explores recent advances in nanocarrier-based drug delivery systems designed to traverse complex biological barriers, with emphasis on transport mechanisms, engineering strategies, clinical translation, and future research directions. We relate barrier anatomy and physiology to nanocarrier trafficking and evaluate barrier-specific strategies, including receptor-mediated transcytosis and focused ultrasound-assisted reversible modulation for the blood–brain barrier, mucoadhesive and amphiphilic systems for ocular delivery, mucus penetration, and endothelial transport. We discussed how particle size, morphology, surface charge, ligand functionalization, and stimulus responsiveness affect barrier transport and therapeutic performance. Clinical translation is discussed through approved formulations and evidence from ongoing clinical trials. Future directions include artificial intelligence-assisted design, predictive modeling of nano-biointerface interactions, cell membrane-based biomimetic nanocarriers, and nanomedicine tailored to patient-specific barrier characteristics. These advances may enable safer, more effective therapies for diseases inadequately addressed by conventional drug delivery.
Related
- Artificial intelligence and machine learning-guided bio-orthogonal engineering of smart soft polymeric nanocarriers for precision drug delivery and translational nanomedicine
- Engineering Morphological Anisotropy to Control the In Vivo Transport Dynamics, Clearance, and Biodistribution of Silica Nanocarriers
- Stimuli-responsive nanocarriers for precision targeted and controlled antimicrobial drug delivery in drug-resistant infections
- Precision chemical engineering of dendrimers for nucleic acid delivery
- Silk biomaterials for precision medicine: From silk science to medical engineering
BibTeX
@article{acharya2026precision,
title = {{Precision engineering of nanocarriers for transport across complex biological barriers}},
author = {Rumi Acharya and Elena Komedchikova and Yonghyun Choi and Jihyuk Yang and Jiwon Kim and Jaewoo Son and Jaehee Jang and Hee-Young Lee and Tetsuya Kadonosono and Jonghoon Choi},
journal = {International Journal of Pharmaceutics: X},
year = {2026},
month = oct,
doi = {10.1016/j.ijpx.2026.100691},
url = {https://doi.org/10.1016/j.ijpx.2026.100691},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Precision engineering of nanocarriers for transport across complex biological barriers
AU - Rumi Acharya
AU - Elena Komedchikova
AU - Yonghyun Choi
AU - Jihyuk Yang
AU - Jiwon Kim
AU - Jaewoo Son
AU - Jaehee Jang
AU - Hee-Young Lee
AU - Tetsuya Kadonosono
AU - Jonghoon Choi
PY - 2026
DA - 2026/10/17
JO - International Journal of Pharmaceutics: X
DO - 10.1016/j.ijpx.2026.100691
UR - https://doi.org/10.1016/j.ijpx.2026.100691
AB - Biological barriers are essential for maintaining tissue homeostasis and protecting organs from harmful external agents; however, they also represent major obstacles to the efficient delivery of therapeutic agents. The blood–brain barrier, ocular barriers, mucosal barriers, and vascular endothelial barriers exhibit highly selective permeability that restricts the transport of both small-molecule drugs and biopharmaceuticals, thereby limiting tissue bioavailability, reducing therapeutic efficacy, and increasing the risk of systemic adverse effects. Advances in nanotechnology have enabled the development of precision-engineered nanocarriers capable of overcoming these barriers through the rational optimization of their physicochemical properties and interactions with biological interfaces. This review comprehensively explores recent advances in nanocarrier-based drug delivery systems designed to traverse complex biological barriers, with emphasis on transport mechanisms, engineering strategies, clinical translation, and future research directions. We relate barrier anatomy and physiology to nanocarrier trafficking and evaluate barrier-specific strategies, including receptor-mediated transcytosis and focused ultrasound-assisted reversible modulation for the blood–brain barrier, mucoadhesive and amphiphilic systems for ocular delivery, mucus penetration, and endothelial transport. We discussed how particle size, morphology, surface charge, ligand functionalization, and stimulus responsiveness affect barrier transport and therapeutic performance. Clinical translation is discussed through approved formulations and evidence from ongoing clinical trials. Future directions include artificial intelligence-assisted design, predictive modeling of nano-biointerface interactions, cell membrane-based biomimetic nanocarriers, and nanomedicine tailored to patient-specific barrier characteristics. These advances may enable safer, more effective therapies for diseases inadequately addressed by conventional drug delivery.
SN - 2590-1567
ER -